Zydus Cadila Launches Ujvira (biosimilar, trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer

 Zydus Cadila Launches Ujvira (biosimilar, trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer

Shots:

  • Ujvira is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) utilizing a stable linker by Antibody Drug Conjugation and is supported by drug development program
  • Ujvira be available in 2 strengths (100 & 60mg) and the therapy will be priced at nearly 80% less than the currently available option in the market (Rs. 1,59,225 for 100 mg vial)
  • Patients already treated with Trastuzumab may still suffer with the disease and would require this therapy as the next step. The expensiveness is a barrier to availing this therapy and Ujvira will resolve this need

Click here to­ read full press release/ article | Ref: Zydus Cadila | Image: Dalal Street Investment Journa

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post